Trials / Completed
CompletedNCT00241020
Evaluation of the Efficacy of Long-acting Release Octreotide in Patients With Advanced Hepatocellular Carcinoma
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 270 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Hepatocellular carcinoma (HCC) is one of the most common malignant disease worldwide with an increasing incidence in industrialized countries. For patients with advanced HCC no efficient treatment is currently available. The objective of this study is to assess the efficacy and safety of octreotide in patients with advanced hepatocellular carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Octreotide |
Timeline
- Start date
- 2002-06-01
- Primary completion
- 2005-10-01
- Completion
- 2005-10-01
- First posted
- 2005-10-18
- Last updated
- 2016-04-12
Source: ClinicalTrials.gov record NCT00241020. Inclusion in this directory is not an endorsement.